Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Wird Global Tactical der nächste Highflyer im Markt für kritische Mineralien?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40GYJ | ISIN: US43906K2096 | Ticker-Symbol:
NASDAQ
23.04.25
18:27 Uhr
0,800 US-Dollar
+0,050
+6,67 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
HOOKIPA PHARMA INC Chart 1 Jahr
5-Tage-Chart
HOOKIPA PHARMA INC 5-Tage-Chart

Aktuelle News zur HOOKIPA PHARMA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
21.02.Poolbeg slumps as Hookipa merger is called off20
HOOKIPA PHARMA Aktie jetzt für 0€ handeln
21.02.Poolbeg shares slide as Hookipa terminates takeover talks6
21.02.Poolbeg Pharma shares plummet as Hookipa walks away from possible bid4
21.02.Poolbeg Pharma PLC - Termination of proposed combination with HOOKIPA5
20.02.Hookipa Pharma rules out making offer for Poolbeg Pharma9
20.02.HOOKIPA Pharma Inc. - 8-K, Current Report-
20.02.US biotech Hookipa retracts merger plans with UK company4
20.02.HOOKIPA Pharma Inc. (";HOOKIPA") Statement regarding potential combination for Poolbeg Pharma plc ("Poolbeg")209NEW YORK and VIENNA, Austria, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE...
► Artikel lesen
30.01.HOOKIPA completes enrollment for HIV vaccine trial6
30.01.HOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV228HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus...
► Artikel lesen
29.01.HOOKIPA Pharma Inc. - 8-K, Current Report1
10.01.HOOKIPA Pharma Inc. - 8-K, Current Report4
10.01.IN BRIEF: Poolbeg Pharma notes Gilead interest in Hookipa fundraise16
10.01.Poolbeg Pharma says Gilead in favour of its combination with Hookipa11
10.01.Poolbeg Pharma plc and HOOKIPA Pharma Inc.: Update on Potential Combination of Poolbeg and HOOKIPA178NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION....
► Artikel lesen
10.01.Poolbeg Pharma PLC - Update Potential Combination of Poolbeg & HOOKIPA7
08.01.HOOKIPA Pharma discloses position in takeover code filing8
08.01.HOOKIPA Pharma Inc.: HOOKIPA Pharma Inc - FORM 8 (OPD)5
07.01.HOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements151NEW YORK and VIENNA, Austria, Jan. 07, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, "HOOKIPA", the "Company"), a clinical-stage biopharmaceutical company developing next generation...
► Artikel lesen
07.01.Form 8.3 - The Vanguard Group, Inc.: HOOKIPA Pharma Inc.332DJ Form 8.3 - The Vanguard Group, Inc.: HOOKIPA Pharma Inc. The Vanguard Group, Inc. ( ) Form 8.3 - The Vanguard Group, Inc.: HOOKIPA Pharma Inc. 07-Jan-2025 / 14:03 GMT/BST =----------------------------------------------------------------------------------------------------------------------...
► Artikel lesen
Seite:  Weiter >>
47 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1